

# Ryusuke Koshida

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9444298/ryusuke-koshida-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

18  
papers

285  
citations

8  
h-index

16  
g-index

18  
ext. papers

382  
ext. citations

8.1  
avg, IF

2.76  
L-index

#	Paper	IF	Citations
18	MAFB prevents excess inflammation after ischemic stroke by accelerating clearance of damage signals through MSR1. <i>Nature Medicine</i> , <b>2017</b> , 23, 723-732	50.5	103
17	Epithelial Pten controls acute lung injury and fibrosis by regulating alveolar epithelial cell integrity. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 262-75	10.2	62
16	MafB is a critical regulator of complement component C1q. <i>Nature Communications</i> , <b>2017</b> , 8, 1700	17.4	30
15	A novel nonsense mutation in the DMP1 gene in a Japanese family with autosomal recessive hypophosphatemic rickets. <i>Journal of Bone and Mineral Metabolism</i> , <b>2010</b> , 28, 585-90	2.9	30
14	Transcription factor MafB may play an important role in secondary hyperparathyroidism. <i>Kidney International</i> , <b>2018</b> , 93, 54-68	9.9	13
13	Generation of insulin-producing cells from the mouse liver using $\beta$ cell-related gene transfer including Mafa and MafB. <i>PLoS ONE</i> , <b>2014</b> , 9, e113022	3.7	11
12	MafB is required for development of the hindbrain choroid plexus. <i>Biochemical and Biophysical Research Communications</i> , <b>2017</b> , 483, 288-293	3.4	10
11	MafB antagonizes phenotypic alteration induced by GM-CSF in microglia. <i>Biochemical and Biophysical Research Communications</i> , <b>2015</b> , 463, 109-15	3.4	9
10	Transcription factor MafB in podocytes protects against the development of focal segmental glomerulosclerosis. <i>Kidney International</i> , <b>2020</b> , 98, 391-403	9.9	5
9	Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22 Suppl 4, 24-34	6.7	4
8	Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24-month interim analysis of a long-term post-marketing study (J-STEP/LT). <i>Journal of Diabetes Investigation</i> , <b>2020</b> , 11, 906-916	3.9	4
7	Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT). <i>Journal of Diabetes Investigation</i> , <b>2021</b> , 12, 184-199	3.9	2
6	Neuron-specific MafB knockout causes growth retardation accompanied by an impaired growth hormone/insulin-like growth factor I axis. <i>Experimental Animals</i> , <b>2019</b> , 68, 435-442	1.8	1
5	Real-world data on the use of insulin glargine 300 U/mL in Japanese patients with type 1 diabetes: twelve-month results from a post-marketing surveillance study (X-STAR study). <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 249-256	4	1
4	Risk of hypoglycemia in Japanese people with type 2 diabetes mellitus who initiated or switched to insulin glargine 300 U/mL: A subgroup analysis of 12-month post-marketing surveillance study (X-STAR study). <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 172, 108647	7.4	0
3	Myosin Id localizes in dendritic spines through the tail homology 1 domain. <i>Experimental Cell Research</i> , <b>2018</b> , 367, 65-72	4.2	
2	Inhibition of epidermal growth factor receptor stimulates prolactin expression in primary culture of the mouse pituitary gland. <i>Journal of Neuroendocrinology</i> , <b>2019</b> , 31, e12764	3.8	

- 1 Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study). *Expert Opinion on Pharmacotherapy*, **2020**, 21, 1771-1780 4